InsiderClue
Stocks · Health care · Pharmaceutical Preparations

BridgeBio Oncology Therapeutics, Inc.

BBOT Clue Score37
United States Fiscal year ends December CIK 0001869105
$3.31 -3.22% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.31 −73.24% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Aug 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−0.0Net income−0.0Fiscal year 2024Operating income−80.9Net income−74.3EPS, diluted−5,756.41Fiscal year 2025Operating income−145.8Net income−134.0EPS, diluted−4.30
FY2023FY2024FY2025
Operating income −0.0 −80.9 −145.8
Net income −0.0 −74.3 −134.0
Growth
EPS, diluted n/a −5,756.41 −4.30

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Fiscal year 2024Operating cash flow−55.0Capital expenditure−0.0Free cash flow−55.1Fiscal year 2025Operating cash flow−113.9Capital expenditure−0.6Free cash flow−114.5
FY2023FY2024FY2025
Operating cash flow n/a −55.0 −113.9
Capital expenditure n/a −0.0 −0.6
Free cash flow n/a −55.1 −114.5
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash0.3Shareholders’ equity−115.6Fiscal year 2024Cash30.9Shareholders’ equity−178.6Fiscal year 2025Cash373.7Shareholders’ equity411.1
FY2023FY2024FY2025
Cash 0.3 30.9 373.7
Shareholders’ equity −115.6 −178.6 411.1

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a n/a −32.6%
−12.5% −45.2% −29.9%
Balance and payout
119.1% 11.9% 8.3%